A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond

Expert Rev Anticancer Ther. 2010 Jun;10(6):955-65. doi: 10.1586/era.10.63.


Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease and have poor long-term prognosis. Gefitinib, a targeted therapy that prevents ATP binding in the tyrosine kinase domain of the EGF receptor, has been subject to comprehensive clinical development. A Phase III trial has demonstrated that gefitinib is superior to carboplatin/paclitaxel in terms of progression-free survival and objective response rate, as first-line treatment for pulmonary adenocarcinoma among never-smokers or former light smokers in East Asia (the IRESSA Pan-Asia Study), with the presence of an EGFR mutation being a strong predictor of the effect of gefitinib compared with carboplatin/paclitaxel. In this article, these results are discussed in the context of other recently reported studies of EGFR mutation-positive patients in both Asian and non-Asian countries. Furthermore, the clinical implications and future challenges for gefitinib are highlighted.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Asia
  • Clinical Trials, Phase III as Topic
  • ErbB Receptors / antagonists & inhibitors*
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy*
  • Precision Medicine
  • Protein Kinase Inhibitors / therapeutic use*
  • Quinazolines / therapeutic use*
  • Treatment Outcome


  • Protein Kinase Inhibitors
  • Quinazolines
  • ErbB Receptors
  • Gefitinib